Compare · GILD vs TSBX
GILD vs TSBX
Side-by-side comparison of Gilead Sciences Inc. (GILD) and Turnstone Biologics Corp. (TSBX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and TSBX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD carries a market cap of $150.83B.
- Over the past year, GILD is up 11.1% and TSBX is down 1.4% - GILD leads by 12.5 points.
- GILD has hit the wire 21 times in the past 4 weeks while TSBX has been quiet.
- GILD has more recent analyst coverage (25 ratings vs 6 for TSBX).
- Company
- Gilead Sciences Inc.
- Turnstone Biologics Corp.
- Price
- $121.46-3.19%
- $0.36+1.63%
- Market cap
- $150.83B
- -
- 1M return
- -9.06%
- -3.58%
- 1Y return
- +11.11%
- -1.44%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- 2023
- News (4w)
- 21
- 0
- Recent ratings
- 25
- 6
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest GILD
- National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership
- Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
- Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa
- GILEAD SCIENCES AND LAKEFRONT COMPLETE ACQUISITION OF OURO MEDICINES TO FURTHER EXPAND INFLAMMATION PIPELINE
- Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline
- Chairman & CEO O'Day Daniel Patrick sold $1,971,847 worth of shares (15,000 units at $131.46) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 617,567 units (SEC Form 4)
- Gilead's Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)
- Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead's Livdelzi (Seladelpar)
- FDA Approval for HEPCLUDEX issued to GILEAD SCIENCES INC
- FDA Grants Accelerated Approval to Gilead's Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)
Latest TSBX
- SEC Form 15-12G filed by Turnstone Biologics Corp.
- SEC Form 4 filed by Director Orbimed Advisors Llc
- Amendment: SEC Form SCHEDULE 13D/A filed by Turnstone Biologics Corp.
- SEC Form 4 filed by Large owner Versant Ventures V, Llc
- SEC Form S-8 POS filed by Turnstone Biologics Corp.
- SEC Form S-8 POS filed by Turnstone Biologics Corp.
- Turnstone Biologics Corp. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant
- Amendment: SEC Form SC 14D9/A filed by Turnstone Biologics Corp.
- SEC Form 25-NSE filed by Turnstone Biologics Corp.
- Amendment: SEC Form SC TO-T/A filed by Turnstone Biologics Corp.